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Pseudomonas aeruginosa bloodstream infection is a serious infection with significant patient mortality and
health-care costs. Nevertheless, the relationship between initial appropriate antimicrobial treatment and
clinical outcomes is not well established. This study was a retrospective cohort analysis employing automated
patient medical records and the pharmacy database at Barnes-Jewish Hospital. Three hundred five patients
with P. aeruginosa bloodstream infection were identified over a 6-year period (January 1997 through December
2002). Sixty-four (21.0%) patients died during hospitalization. Hospital mortality was statistically greater for
patients receiving inappropriate initial antimicrobial treatment (n ⴝ 75) compared to appropriate initial
treatment (n ⴝ 230) (30.7% versus 17.8%; P ⴝ 0.018). Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment (adjusted odds ratio [AOR], 2.04; 95% confidence interval [CI], 1.42
to 2.92; P ⴝ 0.048), respiratory failure (AOR, 5.18; 95% CI, 3.30 to 8.13; P < 0.001), and circulatory shock
(AOR, 4.00; 95% CI, 2.71 to 5.91; P < 0.001) as independent determinants of hospital mortality. Appropriate
initial antimicrobial treatment was administered statistically more often among patients receiving empirical
combination antimicrobial treatment for gram-negative bacteria compared to empirical monotherapy (79.4%
versus 65.5%; P ⴝ 0.011). Inappropriate initial empirical antimicrobial treatment is associated with greater
hospital mortality among patients with P. aeruginosa bloodstream infection. Inappropriate antimicrobial
treatment of P. aeruginosa bloodstream infections may be minimized by increased use of combination antimicrobial treatment until susceptibility results become known.
aeruginosa bloodstream infections. Our second goal was to
examine the relationship between the empirical administration
of combination gram-negative antimicrobial therapy and appropriate treatment for P. aeruginosa bloodstream infections.

Bacterial bloodstream infections are serious infections associated with significant mortality and health-care costs (36). In
many hospitals, Pseudomonas aeruginosa has become the most
common gram-negative bacterial species associated with serious hospital-acquired infections, particularly within intensive
care units (24, 29, 33). The hospital mortality associated with P.
aeruginosa bloodstream infections is reported to be greater
than 20% in most series and is highest among patients receiving inappropriate initial antimicrobial treatment (4, 6, 25, 32,
37). Unfortunately, prior studies of P. aeruginosa bloodstream
infection varied in how they defined appropriate antimicrobial
therapy and did not specifically examine the influence of administering combination antimicrobial agents as a determinant
of appropriate treatment. Additionally, two recent meta-analyses recommend the use of monotherapy with a beta-lactam
antibiotic for the empirical treatment of neutropenic fever and
severe sepsis, infections where P. aeruginosa is often an important pathogen (26, 27).
Due to the clinical importance of bloodstream infections
due to P. aeruginosa, we performed a retrospective cohort
analysis with two main goals. First, we wanted to determine
whether the administration of appropriate initial antimicrobial
treatment was associated with better clinical outcomes for P.

MATERIALS AND METHODS
Study location and patients. This study was conducted at a university-affiliated, urban teaching hospital, Barnes-Jewish Hospital (1,200 beds). During a
6-year period (January 1997 to December 2002), all hospitalized patients with a
positive blood culture for P. aeruginosa were eligible for this investigation. This
study was approved by the Washington University School of Medicine Human
Studies Committee.
Study design and data collection. A retrospective cohort study design was
employed with the main outcome measure being hospital mortality. We also
assessed secondary outcomes, including the administration of appropriate initial
antimicrobial treatment, length of hospitalization, and the occurrence of persistent bacteremia due to P. aeruginosa.
For all study patients the following characteristics were recorded by one of the
investigators (S. T. Micek, A. E. Lloyd, or R. M. Reichley): age, gender, race,
severity of illness based on the simplified acute physiology (SAP) score (21) and
the all patient refined diagnosis related group (APR-DRG) score (30), the
presence of underlying malignancy, neutropenia, infection source, and patient
location at the time of infection. Specific processes of medical care examined
during patients’ hospital stays included mechanical ventilation for respiratory
failure and the administration of vasopressors for circulatory shock. Variables
describing the bloodstream infections and their treatment were also recorded,
including administration of combination antimicrobials for gram-negative bacteria versus monotherapy and the appropriateness of initial antibiotic treatment.
All patient-level data were recorded from automated patient medical records
(EMTEK Health Care Systems Inc., Tempe, Ariz., and Clinical Desktop, BJC
Healthcare, St. Louis, Mo.) and the Barnes-Jewish Hospital Pharmacy automated database, all of which contain prospectively entered information.
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TABLE 1. Baseline characteristics of patients at admission and
infection sourcea
Variable

Age (yrs)
Male gender, n (%)
Race, n (%)
White
African American
Other
Neutropenia, n (%)
Underlying malignancy, n (%)
Patient location, n (%)
Intensive care unit
Hospital ward
Other
SAP score
APR-DRG score
Infection source, n (%)
Lung
Urinary tract
Soft tissue or wound
Unknown
a

Survivors
(n ⫽ 241)

Nonsurvivors
(n ⫽ 64)

P value

58.8 ⫾ 17.9
134 (55.6)

56.0 ⫾ 17.4
39 (60.9)

0.256
0.444

164 (68.0)
68 (28.2)
9 (3.7)
54 (22.4)
100 (41.5)

52 (81.3)
11 (17.2)
1 (1.6)
12 (18.8)
26 (40.6)

0.114

116 (48.1)
116 (48.1)
9 (3.7)
10.9 ⫾ 4.6
3.3 ⫾ 0.7

52 (81.3)
11 (17.2)
1 (1.6)
13.8 ⫾ 5.2
3.9 ⫾ 0.4

⬍0.001

42 (17.4)
49 (20.3)
31 (12.9)
119 (49.4)

24 (37.5)
7 (10.9)
8 (12.5)
25 (39.1)

0.005

0.528
0.900

0.007
⬍0.001

Values presented are means ⫾ standard deviations.

We performed multiple logistic regression analysis using SPSS, version 11.0 for
Windows (SPSS, Inc., Chicago, Ill.). Multivariate analysis was performed using
models that were judged a priori to be clinically sound (7). This was prospectively
determined to be necessary to avoid producing spuriously significant results with
multiple comparisons. All potential risk factors significant at the 0.2 level were
entered into the model. A stepwise approach was used to enter new terms into
the logistic regression model, where hospital mortality was the dependent outcome variable and 0.05 was set as the limit for the acceptance or removal of new
terms.

RESULTS
Patients. A total of 596 consecutive patients with bloodstream infection due to P. aeruginosa were evaluated. Two
hundred twenty-four (37.6%) patients were excluded from
analysis due to the presence of polymicrobial bloodstream
infection. Sixty-seven (11.2%) patients, with a hospital mortality of 55.2%, were excluded due to incomplete information
regarding antimicrobial treatment during the first 24 h following the collection of blood cultures. The remaining 305 patients constituted the study cohort. The mean age of the patients was 58.2 ⫾ 17.8 years (range, 16 to 97 years), and the
mean SAP score was 11.5 ⫾ 4.9 (range, 3 to 26). There were
173 (56.7%) men and 132 (43.3%) women; 216 (70.8%) patients were white, 79 (25.9%) were black, and 10 (3.3%) were
either Hispanic or Asian American.
Patient characteristics according to hospital mortality. Hospital nonsurvivors were statistically more likely to be in an
intensive care unit setting at the time the bloodstream infection was diagnosed, to have the lung identified as the source of
P. aeruginosa bloodstream infection, and to have greater SAP
scores and APR-DRG scores (Table 1). Additionally, hospital
nonsurvivors statistically more often required vasopressors for
circulatory shock and mechanical ventilation for respiratory
failure and developed acute renal failure (Table 2).
Antimicrobial treatment characteristics. The antimicrobial
susceptibilities of the P. aeruginosa bloodstream isolates obtained during the study period are presented in Table 3. Sev-
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A computerized list of patients with a positive blood culture was generated
daily by the Microbiology Laboratory at Barnes-Jewish Hospital, which allowed
identification of potential study patients. Patients could be entered into the study
more than once only if the subsequent episode of P. aeruginosa bacteremia
occurred during a new hospital admission and at least 30 days had elapsed
between positive blood cultures for P. aeruginosa (5).
Definitions. All definitions were selected prospectively as part of the original
study design. We calculated SAP scores on the basis of clinical data available
from the first 24-h period following identification of a positive blood culture (21).
The APR-DRG was also employed to measure severity of illness, using a proprietary method (1, 30). APR-DRGs include four severity-of-illness classes (minor, moderate, major, and extreme) within each DRG, assigned according to a
clinical algorithm evaluating multiple comorbidities, age, procedures, and principal diagnoses (1).
The antimicrobial guidelines for Barnes-Jewish Hospital during the study
period recommended empirical treatment of suspected hospital-acquired bloodstream infections with a combination of an antistaphylococcal drug (vancomycin
for methicillin-resistant staphylococci) and at least one antibiotic, usually a
beta-lactam, with gram-negative activity. For patients at increased risk for infection with antibiotic-resistant gram-negative bacteria (e.g., P. aeruginosa and Acinetobacter species), two antibiotics directed against gram-negative bacteria were
initially recommended (an antipseudomonal beta-lactam or a carbapenem in
combination with an aminoglycoside or a fluoroquinolone). The Barnes-Jewish
Hospital formulary promoted the use of ceftazidime up to 1997 and thereafter
cefepime as the primary antipseudomonal beta-lactam antibiotic. Imipenem and
ciprofloxacin were the formulary carbapenem and fluoroquinolone antibiotics,
respectively, available for clinical use during the entire study period. The antibiotic guidelines recommended modifying the initially prescribed empirical antimicrobial regimens based on the results of clinical cultures and the antimicrobial susceptibility of the identified pathogens. De-escalation or narrowing of the
initial empirically prescribed antimicrobial regimens was monitored by hospital
pharmacists and had to be approved by the patient’s primary physician team (2,
16).
For purposes of this investigation, inappropriate antimicrobial treatment of a
bloodstream infection was defined as the microbiological documentation of infection (i.e., a positive blood culture result) that was not effectively treated at the
time the causative microorganism and its antibiotic susceptibility were known
(15, 17, 19). The microbiology laboratory performed antimicrobial susceptibility
testing of clinical isolates by the Kirby-Bauer disk diffusion method according to
guidelines and breakpoints established by the National Committee for Clinical
Laboratory Standards (23), using 150-mm round plates of Mueller-Hinton agar
(BBL, Becton-Dickinson, Cockeysville, Md.). A technologist experienced in
reading zones of inhibition with a ruler against a black background measured the
zone diameters manually. Inappropriate antimicrobial treatment included the
absence of gram-negative antimicrobial agents with in vitro activity against P.
aeruginosa and the administration of gram-negative antimicrobial agents to
which the P. aeruginosa isolates were resistant based on susceptibility testing.
Circulatory shock was defined as systolic arterial pressure lower than 90 mm
Hg for at least 1 h despite adequate fluid replacement and more than 5 g of
dopamine/kg of body weight or current treatment with epinephrine or norepinephrine (25). Additionally, urinary output of less than 0.5 ml/kg of body weight
for at least 1 h was required for circulatory shock. Respiratory failure was defined
as the need for mechanical ventilation applied by either an endotracheal tube or
by mask.
Blood culture technique. Blood cultures were obtained from two peripheral
sites by nurses or hospital-trained phlebotomists. Before collecting the blood
cultures, skin was disinfected with 70% isopropyl alcohol followed by 2% iodine
tincture. The antecubital fossae were the preferred sampling sites, using sterile
needles and syringes. When only one peripheral site was available and the patient
had a central vein catheter in place, the second blood culture sample was
obtained from the central vein catheter. Injection of 5 ml or less of blood into a
blood culture bottle was not permitted, to avoid false-negative results (35). All
blood samples were inoculated into aerobic medium and processed using the
BACTEC blood culture system (Becton Dickinson, Sparks, Md.).
Statistical analysis. All comparisons were unpaired, and all tests of significance were two-tailed. Continuous variables were compared using the Student t
test for normally distributed variables and the Mann-Whitney U test for nonnormally distributed variables. The chi-square or Fisher’s exact test was used to
compare categorical variables. The primary data analysis compared hospital
nonsurvivors with survivors. Values are expressed as the mean ⫾ standard deviation (continuous variables) or as a percentage of the group from which they
were derived (categorical variables). All P values were two-tailed, and P values of
0.05 or less were considered to indicate statistical significance.
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TABLE 2. Specific organ dysfunction and secondary outcomes

Variable

Survivors (n ⫽ 241)

Nonsurvivors (n ⫽ 64)

P value

Circulatory shock requiring
vasopressors, n (%)
Respiratory failure, n (%)
Acute renal failure, n (%)
Subsequent bacteremia, n (%)
Hospital length of stay, daysa

63 (26.1)

45 (70.3)

⬍0.001

62 (25.7)
24 (10.0)
16 (6.6)
23.9 ⫾ 29.1 (14.0, 4.25–23.75)

45 (70.3)
18 (28.1)
7 (10.9)
44.5 ⫾ 40.8 (27.5, 11.375–43.625)

⬍0.001
⬍0.001
0.247
⬍0.001

a

enty-five (24.6%) patients were treated with inappropriate initial antimicrobial regimens for P. aeruginosa bloodstream
infections. Nine (12.0%) patients treated with inappropriate
initial antimicrobial regimens received no initial gram-negative
antibiotics directed against P. aeruginosa. Sixty-six (88.0%) patients receiving inappropriate therapy were treated with antibiotics having recognized activity against P. aeruginosa but for
which the isolated bacteria were actually resistant by in vitro
susceptibility testing. Patients receiving inappropriate initial
antimicrobial treatment had statistically greater APR-DRG
scores (3.6 ⫾ 0.6 versus 3.3 ⫾ 0.7; P ⫽ 0.014) and statistically
lower rates of neutropenia (5.3% versus 27.0%; P ⬍ 0.001) and
underlying malignancy (30.7% versus 44.8%; P ⫽ 0.031) compared to patients receiving appropriate initial antimicrobial
treatment.
Hospital mortality was statistically greater for patients receiving inappropriate initial antimicrobial treatment (n ⫽ 75)
compared to appropriate initial treatment (n ⫽ 230) (30.7%
versus 17.8%; P ⫽ 0.018). Twenty-nine patients (9.5%) had
inappropriate treatment administered beyond 24 h from initial
antimicrobial treatment but for less than 48 h before changing
to appropriate antimicrobials. These patients had similar hospital mortality to patients receiving appropriate treatment between 24 and 48 h after the start of antibiotics (n ⫽ 276)
(20.7% versus 19.2%; P was not significant). Three patients
received inappropriate antimicrobial treatment beyond 48 h
(100% hospital survival). Inappropriate initial antimicrobial
administration was statistically more likely to occur among
patients receiving monotherapy directed against gram-negative
bacteria compared to those receiving combination therapy
(34.5% versus 20.6%; P ⫽ 0.011). Treatment with ceftazidime
or cefepime was statistically greater among patients receiving
appropriate initial antimicrobial treatment, while the initial

empirical administration of ciprofloxacin was statistically
greater among patients receiving inappropriate treatment (Table 4).
Among patients receiving appropriate initial empirical antimicrobial treatment with a single beta-lactam (n ⫽ 95; mortality ⫽ 12.6%), a single aminoglycoside (n ⫽ 29; mortality ⫽
10.3%), the combination of a beta-lactam and an aminoglycoside (n ⫽ 59; mortality ⫽ 22.0%), or ciprofloxacin alone (n ⫽
15; mortality ⫽ 6.7%), there was no statistical difference in
hospital mortality (P ⫽ 0.214). Similarly, for appropriate definitive antimicrobial treatment there was no statistical difference in hospital mortality among patients receiving a single
beta-lactam (n ⫽ 92; mortality ⫽ 15.2%), the combination of a
beta-lactam and an aminoglycoside (n ⫽ 59; mortality ⫽
22.0%), or ciprofloxacin alone (n ⫽ 14; mortality ⫽ 14.3%) (P
⫽ 0.312). APR-DRG scores (12.1 ⫾ 4.8 versus 10.4 ⫾ 5.0: P ⫽
0.091) and SAP scores (3.4 ⫾ 0.7 versus 3.2 ⫾ 0.8; P ⫽ 0.175)
were not statistically different among patients receiving combination antimicrobial therapy directed against P. aeruginosa
compared to monotherapy.
Multivariate analysis. Multiple logistic regression analysis
identified the administration of inappropriate initial antimicrobial treatment, respiratory failure, and circulatory shock as
independent determinants of hospital mortality (Table 5). The
APR-DRG scores were not entered into the multivariate analysis because no other variables achieved statistical significance
with this variable in the model. All other combinations of
variables entered into the logistic regression analysis yielded a
final model with inappropriate initial antimicrobial treatment
as an independent determinant of hospital mortality. To assess
the importance of inappropriate initial antimicrobial treatment
in potential intermediate variables and confounding variables,
two subgroup analyses were performed. Among the 198 pa-

TABLE 3. Antimicrobial susceptibility of P. aeruginosa bloodstream isolates (n ⫽ 305)a
% Susceptible in:
Antimicrobial(s)

Cefepime
Ceftazidime
Piperacillin-tazobactam
Imipenem-cilastatin
Ciprofloxacin
Gentamicin
Tobramycin

1997 (n ⫽ 52)

1998 (n ⫽ 53)

1999 (n ⫽ 53)

2000 (n ⫽ 50)

2001 (n ⫽ 50)

2002 (n ⫽ 47)

All years

NFb
96.1
NF
88.5
88.5
92.3
94.2

93.8
92.3
96.9
89.2
80.0
90.8
96.9

90.6
NF
92.5
94.3
83.0
92.5
92.5

94.0
NF
92.0
88.0
78.0
92.0
94.0

92.1
NF
94.7
84.2
68.4
92.1
97.4

91.5
NF
91.5
78.7
78.7
100.0
100.0

92.3
94.0
93.7
87.5
80.0
93.1
95.7

a
Resistance to antimicrobial combinations: cefepime or ceftazidime and aminoglycoside, 2.3%; cefepime or ceftazidime and ciprofloxacin, 4.6%; piperacillintazobactam and aminoglycoside, 1.6%; piperacillin-tazobactam and ciprofloxacin, 4%; imipenem-cilastatin and aminoglycoside, 2.3%; imipenem-cilastatin and ciprofloxacin, 5.6%.
b
NF, nonformulary.

Downloaded from http://aac.asm.org/ on March 8, 2014 by Washington University in St. Louis

Values are presented as mean ⫾ SD (median, interquartile range).

PSEUDOMONAS AERUGINOSA BACTEREMIA

VOL. 49, 2005
TABLE 4. Appropriateness of initial antimicrobial treatment
by antibiotica
No. (%)
appropriate
(n ⫽ 230)

No. (%)
inappropriate
(n ⫽ 75)

P value

Cefepime
Ceftazidime
Piperacillin-tazobactam
Imipenem
Aminoglycosideb
Ciprofloxacin
Aztreonam
Other

141 (61.3)
36 (15.7)
5 (2.2)
31 (13.5)
102 (44.3)
32 (13.9)
1 (0.4)
4 (1.7)

33 (44.0)
3 (4.0)
3 (4.0)
9 (12.0)
30 (40.0)
19 (25.3)
0 (0.0)
2 (2.7)

0.009
0.009
0.686
0.742
0.509
0.021
⬎0.999
0.638

a
Appropriate antimicrobial treatment was defined as in vitro susceptibility
testing demonstrating a sensitive isolate of P. aeruginosa to the antimicrobial
agent prescribed.
b
Includes gentamicin, tobramycin, and amikacin.

tients without respiratory failure, inappropriate initial antimicrobial treatment (n ⫽ 43) was associated with a statistically
greater hospital mortality compared to appropriate initial antimicrobial treatment (n ⫽ 155) (18.6% versus 7.1%; P ⫽
0.023). Similarly, among the 197 patients without circulatory
shock, inappropriate initial antimicrobial treatment (n ⫽ 42)
was associated with a greater hospital mortality compared with
appropriate initial antimicrobial treatment (n ⫽ 155) (16.7%
versus 7.7%; P ⫽ 0.082).
Secondary outcomes. Hospital nonsurvivors had statistically
longer hospital lengths of stay than hospital survivors (Table
2). Similarly, patients receiving inappropriate initial antimicrobial treatment had statistically longer hospital lengths of stay
than those receiving appropriate treatment (41.4 ⫾ 47.4 days
versus 23.9 ⫾ 25.2 days; P ⫽ 0.006). Among the hospital
survivors, those receiving inappropriate initial antimicrobial
treatment (n ⫽ 52) had a trend towards longer hospital length
of stay compared to patients receiving appropriate treatment
(n ⫽ 189) (34.0 ⫾ 44.4 days versus 21.1 ⫾ 22.6 days; P ⫽
0.096).
DISCUSSION
Our study demonstrated that inappropriate initial antimicrobial treatment of P. aeruginosa bloodstream infection is associated with statistically greater mortality compared to initial
treatment with an antimicrobial regimen to which the bacteria
were susceptible. Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment as an independent predictor for hospital mortality. Additionally, our data

TABLE 5. Multivariate analysis of independent risk factors for
hospital mortalitya
Predictor

Inappropriate initial antimicrobial treatment
Respiratory failure
Circulatory shock

Adjusted
odds ratio

95% CI

2.04

1.42–2.92

0.048

5.18
4.00

3.30–8.13
2.71–5.91

⬍0.001
⬍0001

P value

a
CI, confidence interval. Note: other covariates not presented in the table had
a P value of ⬎0.05, including race, infection source, acute renal failure, patient
location, and SAP score. Hosmer-Lemeshow deciles of risk statistic, P ⫽ 0.33.

showed that initial treatment with combination antimicrobial
agents directed against P. aeruginosa was statistically more
likely to provide appropriate treatment than was monotherapy.
Finally, the use of fluoroquinolone antibiotics was associated
with a statistically greater likelihood of inappropriate initial
treatment, while cefepime and ceftazidime were statistically
more likely to be associated with appropriate therapy.
Previous investigations have shown that antimicrobial regimens lacking activity against identified microorganisms causing
serious infections (e.g., hospital-acquired pneumonia, bloodstream infections) are associated with greater hospital mortality (15, 17, 19). More recently, the same finding has been
demonstrated for patients with severe sepsis (8, 10, 14). Inappropriate antimicrobial treatment has been shown to be an
important independent risk factor for mortality among hospitalized patients with bloodstream infections (15). Unfortunately, changing antimicrobial therapy to an appropriate regimen after susceptibility data become available has not been
demonstrated to improve clinical outcome (20, 28). These
studies suggest that clinicians should strive to administer appropriate initial antimicrobial treatment for patients with serious infections, including P. aeruginosa bloodstream infections.
In addition to selecting an appropriate initial antimicrobial
regimen, optimal dosing, interval of drug administration, and
duration of treatment are required for antimicrobial efficacy,
limiting toxicity, and to prevent the emergence of bacterial
resistance (18).
This study is unique in having a relatively large population of
patients with P. aeruginosa bloodstream infection for evaluation. Bryan et al. previously found that appropriate antimicrobial therapy for gram-negative bacteremia, on the calendar day
the blood culture was identified to be positive, was not associated with improved survival (4). Appropriate antibiotic treatment subsequent to the first calendar day on which blood
cultures were positive did favorably appear to influence outcomes. Vidal et al. were only able to demonstrate an association between inappropriate definitive antimicrobial treatment
for P. aeruginosa bacteremia and mortality after excluding the
subset of patients with catheter-associated bloodstream infection from their analysis (32). Similarly, Chatzinikolaou et al.
did not find a relationship between the appropriateness of
antibiotic treatment and mortality among cancer patients with
P. aeruginosa infection (6).
Bodey et al. examined 410 episodes of Pseudomonas bacteremia and found that patients receiving appropriate antibiotic
therapy had a greater likelihood of achieving a clinical cure of
their infection (3). This same group of investigators showed
that patients treated with a beta-lactam antibiotic with or without an aminoglycoside had a significantly higher cure rate than
patients who received only an aminoglycoside (3). Similarly,
Chamot and coworkers demonstrated that patients with
Pseudomonas bacteremia treated with combination empirical
antimicrobial therapy until receipt of the antibiogram had a
better 30-day survival compared to monotherapy (5). However,
combination antimicrobial therapy given as definitive treatment for P. aeruginosa bacteremia did not improve the rate of
survival compared to appropriate definitive monotherapy (5).
Our study results are consistent with the findings from these
two investigations. We showed that initial appropriate antimicrobial treatment for P. aeruginosa bacteremia can improve
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infections due to P. aeruginosa. The results from our investigation differ, suggesting that patients with P. aeruginosa bloodstream infection may benefit from the initial administration of
combination antibiotic treatment.
Our study has several important limitations. First, we did not
identify risk factors for the presence of P. aeruginosa bloodstream infection. Earlier reports have demonstrated that prolonged hospitalization, prior treatment with antibiotics, particularly broad-spectrum antibiotics, and colonization with P.
aeruginosa increase the likelihood of infection with this pathogen (9, 18, 31). The presence of such risk factors has been
advocated as a trigger for the empirical treatment of potentially antibiotic-resistant bacteria (31). Second, our study was
performed at a single site and the results may not be applicable
to other settings. However, the consistent relationship demonstrated between inappropriate treatment of serious bacterial
infections and outcome suggests that this is a more universal
finding (17). Third, we did not attempt to directly control the
antimicrobial treatment prescribed to patients. It is possible
that our results would have varied if more rigid antimicrobial
control policies were in place. Nevertheless, only nine (3.0%)
patients were treated initially with antimicrobial agents lacking
potential activity against P. aeruginosa. This was most likely
related to the overall prevalence of P. aeruginosa as a pathogen
in our hospital and the empirical antimicrobial protocols emphasizing the local use of antipseudomonal beta-lactam antibiotics. The greater mortality observed among patients not
included in our analysis due to missing data also suggests the
potential for a reporting bias in our results. Finally, due to the
observational design of this study, a definitive relationship between the use of combination antimicrobial therapy and improved administration of appropriate treatment for P. aeruginosa bloodstream infections cannot be inferred.
In summary, we demonstrated that appropriate initial antimicrobial treatment for P. aeruginosa bloodstream infection
was associated with statistically greater hospital survival. Additionally, the initial empirical use of combination antimicrobial therapy directed against gram-negative bacteria was associated with greater administration of appropriate treatment.
The majority of inappropriate initial antimicrobial treatment
was the consequence of drug resistance, despite promoting
empirical antibiotic regimens with agents having potential activity against P. aeruginosa. This underscores the clinical importance of escalating antimicrobial resistance among bacterial
pathogens. Future studies are needed to define the optimal
strategy for the empirical treatment of patients at risk for P.
aeruginosa bloodstream infection. Until such data become
available, clinicians may consider the use of empirical combination antimicrobial treatment for such patients, balancing this
against the potential for greater toxicity and the emergence of
antimicrobial resistance.
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